Fast Track and IND clearance are positive but expected catalysts for a clinical-stage biotech. The key binary event is the full week-100 VacSYn data in H2 2026.
Price Chart
Executive Summary
AC Immune received FDA Fast Track designation and IND clearance for its wholly owned anti-alpha-synuclein active immunotherapy ACI-7104 for early Parkinson's disease. The regulatory milestones are based on positive interim Phase 2 VacSYn data showing safety, tolerability, and 100% immunogenicity responder rate, with full week-100 results expected in H2 2026.
Key Facts
- FDA granted Fast Track designation and IND clearance for ACI-7104, a wholly owned anti-alpha-synuclein active immunotherapy for early Parkinson's disease.
- Interim Phase 2 VacSYn data at 76 weeks showed safety, tolerability, and 100% immunogenicity responder rate with early signals of activity.
- Full week-100 results from Part 1 of the VacSYn trial are expected in H2 2026.
- AC Immune received a $4 million research grant from the Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the VacSYn trial for two additional years.
- The company has a track record of partnerships with >$4.5 billion in potential milestone payments, though these are for Alzheimer's programs, not ACI-7104.
Financial Impact
Regulatory milestone for a wholly owned program; no financial terms disclosed. The $4M grant supports trial extension but is immaterial relative to potential value of a Parkinson's therapy.
Risk Factors
- Phase 2 week-100 data may fail to confirm efficacy signals seen at 76 weeks.
- Parkinson's disease is a competitive space with multiple anti-synuclein approaches from larger players.
- AC Immune has no approved products and relies on partnerships for funding; ACI-7104 is wholly owned but early-stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342526 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.37 (−3.47%) |
Oct 9, 2026 17d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.37 (−5.40%) |
Oct 2, 2026 24d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.37 (−13.21%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.37 (−16.43%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.37 (−19.28%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.37 (−10.42%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.37 (−10.42%) |
Aug 11, 2026 10w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.37 (−6.89%) |
Aug 11, 2026 10w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.37 (−6.89%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.37 (+3.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers